[September 29, 2016] |
|
Inotek Pharmaceuticals Appoints Timothy Barberich to Board of Directors
Inotek
Pharmaceuticals Corporation (NASDAQ: ITEK) (the "Company" or
"Inotek"), a clinical stage biopharmaceutical company focused on the
discovery, development and commercialization of therapies for ocular
diseases, today announced that Timothy Barberich has been appointed to
its Board of Directors. Mr. Barberich will serve as head of the
Compensation Committee.
Mr. Barberich founded Sepracor Inc. (NASDAQ: SEPR), a publicly-traded,
research-based pharmaceutical company, and served as Chairman and Chief
Executive Officer for over 20 years. Under his leadership, Sepracor
commercialized and partnered several products, including Allegra®,
Brovana®, Clarinex®, Lunesta® and Xopenex®. Before founding Sepracor,
Mr. Barberich was a senior executive at Millipore Corporation. Mr.
Barberich holds a BS degree in chemistry from King's College.
"I'm truly delighted to welcome Tim to Inotek's board. Tim's extensive
experience leading biotech companies from early stage research to
product approvals and commercialization,as well as my longstanding
working relationship with him, make him an ideal addition," said David
P. Southwell, President and Chief Executive Officer. "We are fortunate
to have Tim join us, especially during this important phase of Inotek's
development."
About Inotek Pharmaceuticals Corporation Inotek
Pharmaceuticals is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson,
is a first-in-class selective adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek's
laboratories and is designed to restore the eye's natural pressure
control mechanism. Additionally, the Company is evaluating the potential
for selective adenosine mimetics to address optic neuropathies and other
degenerative retinal diseases. For more information, please visit www.inotekpharma.com.
The inclusion of our website address here and elsewhere in this press
release does not include or incorporate by reference the information on
our website into this press release.
Forward-Looking Statements This press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on these
statements often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "seek," "will," "may" or
similar expressions. Although the Company believes that the expectations
reflected in the forward-looking statements are reasonable, the Company
cannot guarantee such outcomes. Accordingly, you should not place undue
reliance on these forward-looking statements. All such statements speak
only as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160929005201/en/
[ Back To TMCnet.com's Homepage ]
|